REal life study of LEnVAtiNib therapy for HepAtocellular carcinoma: RELEVANT study

Conclusions: Our study confirms in a large and global population of patients wi th advanced HCC not candidate to locoregional treatment the OS reported in the registration study and a high response rate with lenvatinib.
Source: Liver Cancer - Category: Cancer & Oncology Source Type: research